OrbiMed’s Takeda Pharmaceutical TAK Stock Holding History

OrbiMed’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000,000	Closed	-$17.7M	–	138
2019 Q2	$17.7M	Hold	1,000,000	–	–	0.27%	74
2019 Q1	$20.4M	Buy	+1,000,000	New	+$20.1M	0.32%	74

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

OrbiMed's TAK Position: Q4 2019 in Review

OrbiMed sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 750,000 shares — an estimated $12.9M sold.

OrbiMed first reported a position in TAK in Q1 2019 and held it in 3 quarters. The position peaked at $15.3M in Q1 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

OrbiMed reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
OrbiMed sold 750,000 Takeda Pharmaceutical shares in Q4 2019, an estimated $12.9M.
OrbiMed first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 3 quarters.
OrbiMed's Takeda Pharmaceutical position peaked at $15.3M in Q1 2019.
339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.